Citation Impact
Citing Papers
Effect of Clopidogrel Added to Aspirin in Patients with Atrial Fibrillation
2009 Standout
Thromboprophylaxis practice patterns in two Western Australian teaching hospitals.
2004
Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism
2013 Standout
A Meta-Analysis of Thromboembolic Prophylaxis Following Elective Total Hip Arthroplasty*
2000
The Efficacy of Prophylaxis with Low-Dose Warfarin for Prevention of Pulmonary Embolism following Total Hip Arthroplasty*
1997
Nonadherence in outpatient thromboprophylaxis after major orthopedic surgery: a systematic review
2010
Cost-Effectiveness of Prolonged Administration of a Low Molecular Weight Heparin for the Prevention of Deep Venous Thrombosis Following Total Hip Replacement
1999
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies
2008 Standout
Altered venous function and deep venous thrombosis following proximal femoral fracture
2002
Effect of Food, an Antacid, and the H2 Antagonist Ranitidine on the Absorption of BAY 59–7939 (Rivaroxaban), an Oral, Direct Factor Xa Inhibitor, in Healthy Subjects
2006
Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial
2008
Discrepancies between Meta-Analyses and Subsequent Large Randomized, Controlled Trials
1997
Low Molecular Weight Heparin
1997
Assessment of laboratory assays to measure rivaroxaban – an oral, direct factor Xa inhibitor
2010
Evaluation of D-Dimer in the Diagnosis of Suspected Deep-Vein Thrombosis
2003 Standout
Increased activation of coagulation and formation of late deep venous thrombosis following discontinuation of thromboprophylaxis after hip replacement surgery
1995
New oral antithrombotics: a need for laboratory monitoring. For
2010
Novel Anticoagulants for Stroke Prevention in Atrial Fibrillation
2010
Rivaroxaban in Patients with a Recent Acute Coronary Syndrome
2011 Standout
Prevention of VTE in Orthopedic Surgery Patients
2012 Standout
Oral Anticoagulant Therapy
2012 Standout
Fondaparinux vs Enoxaparin for the Prevention of Venous Thromboembolism in Major Orthopedic Surgery<subtitle>A Meta-analysis of 4 Randomized Double-blind Studies</subtitle>
2002
Prevention of venous thromboembolism after knee arthroscopy with low–molecular weight heparin (Reviparin)
2001
Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. A cost-utility analysis.
2004
Comparative Pharmacodynamics and Pharmacokinetics of Oral Direct Thrombin and Factor Xa Inhibitors in Development
2008
Apixaban or Enoxaparin for Thromboprophylaxis after Knee Replacement
2009
Rivaroxaban
2011
Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial
2010
A critical appraisal of bleeding events reported in venous thromboembolism prevention trials of patients undergoing hip and knee arthroplasty
2010
2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults
2009 Standout
Prevention of Venous Thromboembolic Disease After Total Hip and Knee Arthroplasty
2005
New Antithrombotic Drugs
2009
Low-Molecular-Weight Heparin Prophylaxis Using Dalteparin Extended Out-of-Hospital vs In-Hospital Warfarin/Out-of-Hospital Placebo in Hip Arthroplasty Patients
2000
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
2011 Standout
Prevention of VTE in Nonsurgical Patients
2012 Standout
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial
2009
Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials
2013 Standout
Analysis of Missed Cases of Abusive Head Trauma
1999 Standout
Assessing the quality of reports of randomized clinical trials: Is blinding necessary?
1996 Standout
A systematic review of the accuracy of ultrasound in the diagnosis of deep venous thrombosis in asymptomatic patients
2004
Liberal or Restrictive Transfusion in High-Risk Patients after Hip Surgery
2011 Standout
CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials
2010 Standout
Incidence of Venographically Proved Deep Vein Thrombosis After Knee Arthroscopy
1998
Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study
2008 Standout
BAY 59-7939: an oral, direct Factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study
2005
Risk Factors for Venous Thromboembolism in Patients Undergoing Total Hip Replacement and Receiving Routine Thromboprophylaxis
2010
Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism
2009 Standout
Association between asymptomatic deep vein thrombosis detected by venography and symptomatic venous thromboembolism in patients undergoing elective hip or knee surgery
2007
The potential role of new oral anticoagulants in the prevention and treatment of thromboembolism
2010
The Assessment of Deep Vein Thromboses for Therapeutic Trials
2003
Guidelines on the use and monitoring of heparin
2006
Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement
2010
Cell biology of tissue factor, the principal initiator of blood coagulation
1996
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration
2009 Standout
Safety, pharmacokinetics and pharmacodynamics of single doses of rivaroxaban – an oral, direct factor Xa inhibitor – in elderly Chinese subjects
2009
Thromboprophylaxis and death after total hip replacement
1996
Nonaccidental Head Injury in Infants — The “Shaken-Baby Syndrome”
1998 Standout
Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients
2009 Standout
A Prospective Study of Venous Thromboembolism after Major Trauma
1994 Standout
Low Molecular Weight Heparin and Unfractionated Heparin in Thrombosis Prophylaxis: Meta-Analysis Based on Original Patient Data
2001
Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement
1999 Standout
Clinical relevance of the fibrinogen uptake test in patients undergoing elective general abdominal surgery—relation to major thromboembolism and mortality
1995
Apixaban versus Enoxaparin for Thromboprophylaxis after Hip Replacement
2010
Duration of Prophylaxis against Venous Thromboembolism with Enoxaparin after Surgery for Cancer
2002 Standout
Monitoring direct FXa-inhibitors and fondaparinux by Prothrombinase-induced Clotting Time (PiCT): Relation to FXa-activity and influence of assay modifications
2008
Low-Molecular-Weight Heparin Prophylaxis Using Dalteparin in Close Proximity to Surgery vs Warfarin in Hip Arthroplasty Patients
2000
Prevention of Venous Thromboembolism
2004 Standout
The Hazards of Scoring the Quality of Clinical Trials for Meta-analysis
1999 Standout
Venous thromboembolism and its prevention in critical care
2002
Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Rivaroxaban—an Oral, Direct Factor Xa Inhibitor—Are Not Affected by Aspirin
2006
Low-Molecular-Weight Heparin (Enoxaparin) as Prophylaxis against Venous Thromboembolism after Total Hip Replacement
1996
Effects of the Oral, Direct Factor Xa Inhibitor Rivaroxaban on Platelet‐Induced Thrombin Generation and Prothrombinase Activity1
2007
Randomized, Controlled Trials, Observational Studies, and the Hierarchy of Research Designs
2000 Standout
A Comparison of Subcutaneous Low-Molecular-Weight Heparin with Warfarin Sodium for Prophylaxis against Deep-Vein Thrombosis after Hip or Knee Implantation
1993
Idarucizumab for Dabigatran Reversal
2015 Standout
Prevention of Venous Thromboembolism
2008 Standout
Future directions of stroke prevention in atrial fibrillation: the potential impact of novel anticoagulants and stroke risk stratification
2010
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for Reporting Observational Studies
2007 Standout
Ultrasound screening for asymptomatic deep vein thrombosis after major orthopaedic surgery: the VENUS study
2007
Reporting of Noninferiority and Equivalence Randomized Trials
2012 Standout
Disseminated Intravascular Coagulation
1999 Standout
A Comparison of Low-Molecular-Weight Heparin with Unfractionated Heparin for Unstable Coronary Artery Disease
1997 Standout
Epidural anaesthesia and analgesia and outcome of major surgery: a randomised trial
2002 Standout
A comparison of intermittent calf compression and enoxaparin for thromboprophylaxis in total hip replacement
1997
Safety, pharmacokinetics and pharmacodynamics of single/multiple doses of the oral, direct Factor Xa inhibitor rivaroxaban in healthy Chinese subjects
2009
Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial
2009
Risk assessment of venous thromboembolism in hospitalized medical patients
2010
Feasibility and Safety of Dabigatran Versus Warfarin for Periprocedural Anticoagulation in Patients Undergoing Radiofrequency Ablation for Atrial Fibrillation
2012
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration
2009 Standout
Deep vein thrombosis
2005
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies
2007 Standout
A dose‐ranging study evaluating the oral factor Xa inhibitor edoxaban for the prevention of venous thromboembolism in patients undergoing total knee arthroplasty
2010
Preoperative vs Postoperative Initiation of Low-Molecular-Weight Heparin Prophylaxis Against Venous Thromboembolism in Patients Undergoing Elective Hip Replacement
1999
Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery: a meta-analysis
1992
A Comparison of Enoxaparin with Placebo for the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients
1999 Standout
The Incidence of Symptomatic Venous Thromboembolism During and After Prophylaxis With Enoxaparin<subtitle>A Multi-institutional Cohort Study of Patients Who Underwent Hip or Knee Arthroplasty</subtitle>
1998
Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II)
2011
Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays
2010 StandoutNobel
Bilateral vs. ipsilateral venography as the primary efficacy outcome measure in thromboprophylaxis clinical trials: a systematic review
2004
Prevention of Venous Thromboembolism
1998
Role of Orally Available Antagonists of Factor Xa in the Treatment and Prevention of Thromboembolic Disease: Focus on Rivaroxaban
2010
Deep Venous Thrombosis after Total Joint Arthroplasty. The Role of Compression Ultrasonography and the Importance of the Experience of the Technician*
1996
Coagulation and Fibrinolysis during Laparoscopic Cholecystectomy
1999
Low Accuracy of Color Doppler Ultrasound in the Detection of Proximal Leg Vein Thrombosis in Asymptomatic High-Risk Patients
1992
Body Weight Has Limited Influence on the Safety, Tolerability, Pharmacokinetics, or Pharmacodynamics of Rivaroxaban (BAY 59‐7939) in Healthy Subjects
2007
Rivaroxaban (BAY 59‐7939) – an oral, direct Factor Xa inhibitor – has no clinically relevant interaction with naproxen
2006
Prospective Surveillance for Perioperative Venous Thrombosis
1996
The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration
2009 Standout
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
2011 Standout
Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty
2010
Low molecular weight heparin in prevention of perioperative thrombosis.
1992
Extended Out-of-Hospital Low-Molecular-Weight Heparin Prophylaxis against Deep Venous Thrombosis in Patients after Elective Hip Arthroplasty
2001
Heparins and mechanical methods for thromboprophylaxis in colorectal surgery
2003
Standardized Bleeding Definitions for Cardiovascular Clinical Trials
2011 Standout
Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion
2016 Standout
Better Reporting of Harms in Randomized Trials: An Extension of the CONSORT Statement
2004
THROMBOPROPHYLAXIS AND DEATH AFTER TOTAL HIP REPLACEMENT
1996
Post Discharge Clinically Overt Venous Thromboembolism in Orthopaedic Surgery Patients with Negative Venography -an Overview Analysis
1996
State-of-the-Art Review: Assessing the Safety Profiles of New Anticoagulants for Major Orthopedic Surgery Thromboprophylaxis
2009
Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects
2008
Low Molecular Weight Heparin
1997
Oral Rivaroxaban for Symptomatic Venous Thromboembolism
2010 Standout
Comparing the Costs, Risks, and Benefits of Competing Strategies for the Primary Prevention of Venous Thromboembolism
2004
Perioperative low-molecular-weight heparin. Is it effective and safe
1995
A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein–DVT Dose-Ranging Study
2008
Coagulopathy in Pediatric Abusive Head Trauma
1997
Incidence, Natural History and Risk Factors of Deep Vein Thrombosis in Elective Knee Arthroscopy
2001
Low molecular weight heparin for prevention of venous thromboembolism in patients with lower-limb immobilization
2017
Prevention of Venous Thromboembolism in the Acute Treatment Phase after Spinal Cord Injury: A Randomized, Multicenter Trial Comparing Low-Dose Heparin Plus Intermittent Pneumatic Compression with Enoxaparin
2003
Hospitals’ compliance with prophylaxis guidelines for venous thromboembolism
2006
Color Doppler Flow Imaging For Deep Venous Thrombosis Screening in Patients Undergoing Pelvic Lymphadenectomy and Radical Retropubic Prostatectomy for Prostatic Carcinoma
1995
Prophylaxis of postoperative thromboembolism with low molecular weight heparins
1993
Challenges of Establishing New Antithrombotic Therapies in Atrial Fibrillation
2007
A venous foot pump reduces thrombosis after total hip replacement
1992
Duplex Ultrasonography for the Detection of Deep Vein Thrombi After Total Hip or Knee Arthroplasty
1993
Heparin, low molecular weight heparin and physical methods for preventing deep vein thrombosis and pulmonary embolism following surgery for hip fractures
2002
Major Bleeding, Mortality, and Efficacy of Fondaparinux in Venous Thromboembolism Prevention Trials
2009
Low risk of thromboembolic complications after fast-track hip and knee arthroplasty
2010
Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement
2009
Assessing the quality of reports of randomised trials: implications for the conduct of meta-analyses.
1999
Timing of initial administration of low-molecular-weight heparin prophylaxis against deep vein thrombosis in patients following elective hip arthroplasty: a systematic review.
2001
A Meta-analysis of Methods to Prevent Venous Thromboembolism Following Total Hip Replacement
1994
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation
2014 Standout
Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism
2012 Standout
Noninvasive Diagnosis of Deep Venous Thrombosis
1998
The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration
2009 Standout
Prevention of deep vein thrombosis after hip replacement--comparison between two low-molecular heparins, tinzaparin and enoxaparin.
1999
Low-Molecular-Weight Heparins
1997 Standout
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for Reporting Observational Studies
2007 Standout
Diagnostic Accuracy of Compression Ultrasonography for the Detection of Asymptomatic Deep Venous Thrombosis in Medical Patients
2001
The Halogen Bond
2016 Standout
Treatment of Proximal Deep-Vein Thrombosis With the Oral Direct Factor Xa Inhibitor Rivaroxaban (BAY 59-7939)
2007
Low molecular weight heparin and unfractionated heparin in thrombosis prophylaxis after major surgical intervention: Update of previous meta-analyses
1997
Low molecular weight heparin started before surgery as prophylaxis against deep vein thrombosis: 2500 versus 5000 Xal units in 2070 patients
1995
Prevention of Venous Thromboembolism
1995
Impedance Plethysmography in the Diagnosis of Asymptomatic Deep Vein Thrombosis in Hip Surgery
1991
Design, Structure−Activity Relationships, X-ray Crystal Structure, and Energetic Contributions of a Critical P1 Pharmacophore: 3-Chloroindole-7-yl-Based Factor Xa Inhibitors
2008
Prolonged Thromboprophylaxis With Dalteparin After Surgical Treatment of Achilles Tendon Rupture: A Randomized, Placebo-Controlled Study
2007
Graduated compression stockings in the prevention of venous thromboembolism
1999
The Use of Soluble Fibrin in Evaluating the Acute and Chronic Hypercoagulable State
1999
Early Preoperative Thromboprophylaxis with Klexane® in Hip Fracture Surgery: A Placebo-Controlled Study
1998
Assessment of venous thromboembolism risk and the benefits of thromboprophylaxis in medical patients
2005
Natural History of Thromboembolic Disease After Total Hip Arthroplasty
1996
Low-Molecular-Weight Heparinoid Orgaran Is More Effective Than Aspirin in the Prevention of Venous Thromboembolism After Surgery for Hip Fracture
1996
Prevention of Deep Vein Thrombosis after Hip Replacement
1999
Economic evaluation of the use of enoxaparin for thromboprophylaxis in acutely ill medical patients
2001
Rivaroxaban: A New Oral Factor Xa Inhibitor
2010
Prevention of Venous Thromboembolism in the Acute Treatment Phase after Spinal Cord Injury
2003
Cost-effectiveness of Enoxaparin vs Low-Dose Warfarin in the Prevention of Deep-Vein Thrombosis After Total Hip Replacement Surgery
1995
Works of Lars C. Borris being referenced
Rivaroxaban for thromboprophylaxis after orthopaedic surgery: Pooled analysis of two studies
2007
Prevention of thromboembolism in hip-fracture patients
1989
Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Total Knee Arthroplasty
2008
Blood Transfusion and Overall Quality of Life After Hip Fracture in Frail Elderly Patients—The Transfusion Requirements in Frail Elderly Randomized Controlled Trial
2015
Population Pharmacokinetics and Pharmacodynamics of Rivaroxaban – an Oral, Direct Factor Xa Inhibitor – in Patients Undergoing Major Orthopaedic Surgery
2008
Potential Influence of Observer Variation in Thromboprophylactic Trials
1992
Dose-escalation study of rivaroxaban (BAY 59-7939) – an oral, direct Factor Xa inhibitor – for the prevention of venous thromboembolism in patients undergoing total hip replacement
2007
Components of coagulation and fibrinolysis during thrombosis prophylaxis with a low molecular weight heparin (Enoxaparin) versus Dextran 70 in hip arthroplasty
1991
Barriers to the optimal use of anticoagulants after orthopaedic surgery
2008
Venography in Deep Venous Thrombosis: Postoperative Screening of Patients in Prophylaxis Studies
1993
Poor correlation between soluble fibrin concentrations measured by two commercially available immunoassays
1996
Thromboprophylaxis with Low Molecular Weight Heparin after Major Orthopaedic Surgery is Cost Effective
1996
Haemostatic activation in patients with head injury with and without simultaneous multiple trauma
1993
Markers of coagulation and fibrinolysis after fractures of the lower extremities
1992
Blood transfusion and risk of infection in frail elderly after hip fracture surgery: the TRIFE randomized controlled trial
2015
Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Hip Arthroplasty
2008 Standout
Oral, direct Factor Xa inhibition with BAY 59‐7939 for the prevention of venous thromboembolism after total hip replacement
2005
Real-time B-mode ultrasonography in the diagnosis of postoperative deep vein thrombosis in non-symptomatic high-risk patients
1990
Thromboembolic complications after arthroscopy of the knee
1993
Measuring the Outcomes and Pharmacoeconomic Consequences of Venous Thromboembolism Prophylaxis in Major Orthopaedic Surgery
2003
Prevention of thromboembolism in 190 hip arthroplasties: Comparison of LMW heparin andplacebo
1991
Biologic Tolerance of Two Different Low Molecular Weight Heparins
1991
Association between plasma levels of tissue plasminogen activator and postoperative deep vein thrombosis-influence of prophylaxis with a low molecular weight heparin
1990
Heparin/dihydroergotamine for venous thrombosis prophylaxis: comparison of low-dose heparin and low molecular weight heparin in hip surgery
1988
Clinical limitations of risk assessment models.
1999
Rivaroxaban for Thromboprophylaxis in Patients Undergoing Total Hip Replacement: Comparison of Pharmacokinetics and Pharmacodynamics with Once- and Twice-Daily Dosing.
2006
Population pharmacokinetics and pharmacodynamics of once and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement
2008
Reduction of plasma levels of prothrombin fragments 1 and 2 during thromboprophylaxis with a low-molecular-weight heparin
1992
Rivaroxaban - An Oral, Direct Factor Xa Inhibitor - for Thromboprophylaxis after Total Knee Arthoplasty: The RECORD3 Trial.
2007
Perioperative thrombosis prophylaxis with low molecular weight heparins in elective hip surgery. Clinical and economic considerations.
1994
Prevention of Venous Thromboembolism after Total Hip Replacement with Once-Daily BAY 59-7939 - An Oral, Direct Factor Xa Inhibitor.
2005
A Once-Daily, Oral, Direct Factor Xa Inhibitor, Rivaroxaban (BAY 59-7939), for Thromboprophylaxis After Total Hip Replacement
2006
Phlebography as the Gold Standard in Thromboprophylactic Studies?
1992
Comparison of Real-Time B-Mode Ultrasonog raphy and Bilateral Ascending Phlebography for Detection of Postoperative Deep Vein Thrombosis Following Elective Hip Surgery
1989
Role of tissue factor pathway inhibitor in post surgical deep venous thrombosis (DVT) prophylaxis in patients treated with low molecular weight heparin
1994
Biological tolerance of Logiparin, a low molecular weight heparin used in patients undergoing total hip replacement.
1991
Phlebography as the Gold Standard in Thromboprophylactic Studies?
1992
Levels of thrombin - antithrombin-III complex and factor VIII activity in relation to post-operative deep vein thrombosis and influence of prophylaxis with a low-molecular-weight heparin
1990
Use of the Low-Molecular-Weight Heparin Reviparin to Prevent Deep-Vein Thrombosis after Leg Injury Requiring Immobilization
2002
Oral Rivaroxaban Compared with Subcutaneous Enoxaparin for Extended Thromboprophylaxis after Total Hip Arthroplasty: The RECORD1 Trial.
2007
Postoperative blood transfusion strategy in frail, anemic elderly patients with hip fracture
2015
Clinical trials with low molecular weight heparins in the prevention of postoperative thromboembolic complications: a meta-analysis.
1991
Major joint replacement. A model for antithrombotic drug development: from proof-of-concept to clinical use.
2008